irinotecan has been researched along with thiourea in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nazha, B; Owonikoko, TK | 1 |
| Corbacioglu, S; Heise, T; Leister, J; Matthes, M; Penkivech, G; Sommer, G; Waetzig, R | 1 |
2 other study(ies) available for irinotecan and thiourea
| Article | Year |
|---|---|
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan | 2019 |
Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
Topics: Administration, Metronomic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Irinotecan; Naphthyridines; Neuroblastoma; Purines; Pyrimidines; Signal Transduction; Sirolimus; Temozolomide; Thiourea; TOR Serine-Threonine Kinases | 2021 |